Search results
Blockbuster deals are shaping key player CMOs despite 31% drop in M&A
Pharmaceutical Technology via Yahoo Finance· 13 minutes agoIn June 2023, Roche disclosed its plans to close the legacy Genentech (South San Francisco, US)...
Slow recovery for life science
San Mateo Daily Journal· 2 hours agoStiffening regulation, government shortfalls and long-term leasing trends are contributing to the life science industry’s sluggish recovery, marked by...
Sanofi heads out to surf Belharra in $700M biobucks immunology deal
FierceBiotech· 6 days agoSanofi is offering Belharra Therapeutics up to $700 million in biobucks for a tow out to surf the...
Rethinking Clinical Trial Design and Cure in NSCLC
Medscape· 4 days agoMark Kris discusses clinical trial design and the goal of cure in non–small cell lung cancer.
Community pharmacists join the PBM ad frenzy
Politico· 7 days ago...Tim Kennedy (D-N.Y.) and Mike Lawler (R-N.Y.); Sam Hewitt of the American Nurses Association, Jill Shotzberger of Genentech, Jamie Miller of the American Medical Group Association, Pam Roberto of PhRMA, Monet Sanford of the Alliance for Regenerative ...
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
BioPharma Dive via Yahoo Finance· 6 days agoBelharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere,...
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
MedPage Today· 5 days agoHigh-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line
The warehouse where Pride Parade comes alive
The San Francisco Examiner· 5 days agoThe standout features are a mostly empty parking lot off Terry Francois Boulevard, a metal chain-link fence, and a cavernous, yet unassuming warehouse...
ASCO 2024: How to Best Use New Breast Cancer Data
Medscape· 4 days agoKevin Kalinsky and Sara Hurvitz discuss the results of awaited data in the breast cancer space presented at the 2024 ASCO Annual Meeting.
Beyond BCMA-Directed CAR T-Cell Therapy
MedPage Today· 3 days agoAlthough survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment....
